Breaking News, Collaborations & Alliances

GIBF Invests $10M in Nectin Therapeutics

The funds will be used to continue the development of Nectin's portfolio of novel immuno-oncology products.

Author Image

By: Charlie Sternberg

Associate Editor

Guangzhou-Israel Biotechnology Fund (GIBF) has invested $10 million in Nectin Therapeutics Ltd., a biotechnology company developing novel targeted immunotherapies that address resistance to approved immune oncology treatments.   The funds will be used to continue the development of Nectin’s portfolio of novel immuno-oncology products, including the advancement of Nectin’s ongoing NTX1088 global Phase 1 clinical trial targeting PVR and the preclinical development of its anti-drug co...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters